Repligen Corp (RGEN)

$134.49

-2.06

(-1.51%)▲

Market is closed - opens 7 PM, 11 Oct 2024

Performance

  • $133.73
    $135.63
    $134.49
    downward going graph

    0.57%

    Downside

    Day's Volatility :1.4%

    Upside

    0.84%

    downward going graph
  • $110.45
    $211.13
    $134.49
    downward going graph

    17.87%

    Downside

    52 Weeks Volatility :47.69%

    Upside

    36.3%

    downward going graph

Returns

PeriodRepligen CorpSector (Health Care)Index (Russel 2000)
3 Months
12.9%
4.8%
0.0%
6 Months
-22.41%
8.3%
0.0%
1 Year
-12.03%
17.0%
0.0%
3 Years
-46.18%
20.8%
-20.8%

Highlights

Market Capitalization
7.6B
Book Value
$35.53
Earnings Per Share (EPS)
-0.03
PEG Ratio
2.59
Wall Street Target Price
193.32
Profit Margin
-0.32%
Operating Margin TTM
1.6%
Return On Assets TTM
0.2%
Return On Equity TTM
-0.1%
Revenue TTM
602.4M
Revenue Per Share TTM
10.79
Quarterly Revenue Growth YOY
-3.2%
Gross Profit TTM
455.7M
EBITDA
78.9M
Diluted Eps TTM
-0.03
Quarterly Earnings Growth YOY
-0.83
EPS Estimate Current Year
1.42
EPS Estimate Next Year
1.81
EPS Estimate Current Quarter
0.33
EPS Estimate Next Quarter
0.38

Analyst Recommendation

Buy
    78%Buy
    21%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Repligen Corp(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 43.74%

Current $134.49
Target $193.32

Company Financials

FY18Y/Y Change
Revenue
194.0M
↑ 37.38%
Net Income
16.6M
↓ 41.39%
Net Profit Margin
8.56%
↓ 11.51%
FY19Y/Y Change
Revenue
270.2M
↑ 39.28%
Net Income
21.4M
↑ 28.85%
Net Profit Margin
7.92%
↓ 0.64%
FY20Y/Y Change
Revenue
366.3M
↑ 35.53%
Net Income
59.9M
↑ 179.88%
Net Profit Margin
16.36%
↑ 8.44%
FY21Y/Y Change
Revenue
670.5M
↑ 83.08%
Net Income
128.3M
↑ 114.08%
Net Profit Margin
19.13%
↑ 2.77%
FY22Y/Y Change
Revenue
801.5M
↑ 19.54%
Net Income
186.0M
↑ 44.95%
Net Profit Margin
23.2%
↑ 4.07%
FY23Y/Y Change
Revenue
638.8M
↓ 20.31%
Net Income
41.6M
↓ 77.64%
Net Profit Margin
6.51%
↓ 16.69%
Q1 FY23Q/Q Change
Revenue
182.7M
↓ 2.2%
Net Income
28.8M
↓ 40.84%
Net Profit Margin
15.78%
↓ 10.31%
Q2 FY23Q/Q Change
Revenue
159.2M
↓ 12.86%
Net Income
20.1M
↓ 30.4%
Net Profit Margin
12.61%
↓ 3.17%
Q3 FY23Q/Q Change
Revenue
141.2M
↓ 11.29%
Net Income
18.2M
↓ 9.43%
Net Profit Margin
12.87%
↑ 0.26%
Q4 FY23Q/Q Change
Revenue
155.7M
↑ 10.31%
Net Income
-25.5M
↓ 240.26%
Net Profit Margin
-16.37%
↓ 29.24%
Q1 FY24Q/Q Change
Revenue
151.3M
↓ 2.82%
Net Income
2.1M
↓ 108.22%
Net Profit Margin
1.38%
↑ 17.75%
Q2 FY24Q/Q Change
Revenue
154.1M
↑ 1.8%
Net Income
3.3M
↑ 58.6%
Net Profit Margin
2.16%
↑ 0.78%
FY18Y/Y Change
Total Assets
139.5M
↑ 15.81%
Total Liabilities
155.0M
↑ 2.04%
FY19Y/Y Change
Total Assets
1.4B
↑ 904.03%
Total Liabilities
340.3M
↑ 119.55%
FY20Y/Y Change
Total Assets
1.9B
↑ 35.91%
Total Liabilities
373.7M
↑ 9.81%
FY21Y/Y Change
Total Assets
2.4B
↑ 23.94%
Total Liabilities
608.3M
↑ 62.76%
FY22Y/Y Change
Total Assets
2.5B
↑ 7.05%
Total Liabilities
614.0M
↑ 0.93%
FY23Y/Y Change
Total Assets
2.8B
↑ 11.87%
Total Liabilities
853.2M
↑ 38.97%
Q1 FY23Q/Q Change
Total Assets
2.5B
↑ 0.54%
Total Liabilities
597.7M
↓ 2.64%
Q2 FY23Q/Q Change
Total Assets
2.5B
↑ 0.42%
Total Liabilities
578.1M
↓ 3.29%
Q3 FY23Q/Q Change
Total Assets
2.5B
↓ 1.37%
Total Liabilities
525.6M
↓ 9.08%
Q4 FY23Q/Q Change
Total Assets
2.8B
↑ 12.34%
Total Liabilities
853.2M
↑ 62.34%
Q1 FY24Q/Q Change
Total Assets
2.8B
↑ 0.88%
Total Liabilities
878.7M
↑ 2.98%
Q2 FY24Q/Q Change
Total Assets
2.9B
↑ 0.44%
Total Liabilities
875.6M
↓ 0.35%
FY18Y/Y Change
Operating Cash Flow
32.8M
↑ 87.78%
Investing Cash Flow
-14.0M
↓ 85.71%
Financing Cash Flow
3.4M
↓ 97.38%
FY19Y/Y Change
Operating Cash Flow
67.2M
↑ 105.11%
Investing Cash Flow
-205.3M
↑ 1362.62%
Financing Cash Flow
484.9M
↑ 14131.49%
FY20Y/Y Change
Operating Cash Flow
62.6M
↓ 6.83%
Investing Cash Flow
-201.4M
↓ 1.91%
Financing Cash Flow
305.9M
↓ 36.91%
FY21Y/Y Change
Operating Cash Flow
119.0M
↑ 90.05%
Investing Cash Flow
-221.2M
↑ 9.82%
Financing Cash Flow
961.0K
↓ 99.69%
FY22Y/Y Change
Operating Cash Flow
172.1M
↑ 44.59%
Investing Cash Flow
-233.2M
↑ 5.46%
Financing Cash Flow
-13.3M
↓ 1487.83%
Q1 FY23Q/Q Change
Operating Cash Flow
11.2M
↓ 81.98%
Investing Cash Flow
-9.4M
↓ 92.22%
Financing Cash Flow
-9.6M
↑ 3390.15%
Q2 FY23Q/Q Change
Operating Cash Flow
34.5M
↑ 209.02%
Investing Cash Flow
64.8M
↓ 787.3%
Financing Cash Flow
-8.8M
↓ 7.72%

Technicals Summary

Sell

Neutral

Buy

Repligen Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Repligen Corp
Repligen Corp
-6.92%
-22.41%
-12.03%
-46.18%
79.91%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
1.27%
26.24%
64.65%
51.27%
187.76%
Resmed Inc.
Resmed Inc.
-6.26%
22.31%
57.6%
-5.79%
81.68%
Becton, Dickinson And Company
Becton, Dickinson And Company
1.07%
-1.15%
-10.86%
1.01%
-4.16%
Alcon Ag
Alcon Ag
-1.71%
17.34%
25.87%
22.71%
71.48%
Cooper Companies Inc., The
Cooper Companies Inc., The
-1.42%
10.67%
-66.22%
5.74%
46.9%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Repligen Corp
Repligen Corp
492.86
NA
2.59
1.42
0.0
0.0
NA
35.53
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
83.97
83.97
4.15
6.65
0.16
0.08
NA
41.4
Resmed Inc.
Resmed Inc.
34.25
34.25
1.98
7.71
0.23
0.13
0.01
33.11
Becton, Dickinson And Company
Becton, Dickinson And Company
47.83
47.83
1.09
13.11
0.06
0.03
0.02
89.5
Alcon Ag
Alcon Ag
43.44
43.44
3.6
3.06
0.05
0.03
0.0
42.35
Cooper Companies Inc., The
Cooper Companies Inc., The
59.66
59.66
10.7
3.66
0.05
0.03
NA
39.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Repligen Corp
Repligen Corp
Buy
$7.6B
79.91%
492.86
-0.32%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$174.3B
187.76%
83.97
27.65%
Resmed Inc.
Resmed Inc.
Buy
$34.8B
81.68%
34.25
21.79%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$68.9B
-4.16%
47.83
7.13%
Alcon Ag
Alcon Ag
Buy
$47.6B
71.48%
43.44
11.44%
Cooper Companies Inc., The
Cooper Companies Inc., The
Buy
$21.3B
46.9%
59.66
9.45%

Insights on Repligen Corp

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 151.34M → 154.07M (in $), with an average increase of 1.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -25.48M → 3.32M (in $), with an average increase of 677.1% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 64.7% return, outperforming this stock by 76.7%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 49.3% return, outperforming this stock by 96.5%

Institutional Holdings

  • BlackRock Inc

    13.51%

  • Vanguard Group Inc

    9.05%

  • T. Rowe Price Associates, Inc.

    8.23%

  • State Street Corp

    3.10%

  • FMR Inc

    2.58%

  • Sands Capital Management, LLC

    2.54%

Company Information

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.

Organization
Repligen Corp
Employees
1783
CEO
Mr. Anthony J. Hunt
Industry
Health Technology

Discover More

FAQs